---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103526"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:50.788825+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027

## Summary
- Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.
- Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.
- SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.
- Fast Track designation granted by FDA for bempikibart in alopecia areata.
- Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer.

## SEC filing metadata
- accession: 0000950170-25-103526
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/0000950170-25-103526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/qttb-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103526
- JSON: https://secwatch.observer/filing/0000950170-25-103526.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.